Differential COVID-19 vaccination uptake and associated factors among the slum and estate communities in Uganda: a cross-sectional population-based survey
Loading...
Date
2023-02
Journal Title
Journal ISSN
Volume Title
Publisher
MDPI
Abstract
Vaccination against COVID-19 remains one of the ultimate solutions to the ongoing pandemic.
This study examined and compared the completion of primary COVID-19 vaccination series
and associated factors in the slum and estate communities of Uganda. This was a cross-sectional
survey conducted among 1025 slum and estate residents. Logistic regression models were fitted.
Of the 1025 participants, 511 were slum residents and 514 were estate residents. Completion of
COVID-19 vaccination was 43.8% in the slum community and 39.9% in the estate community
(p = 0.03). Having more knowledge about COVID-19 was positively associated with completing
COVID-19 vaccination in both communities. Perceived benefits and cues to action also had a positive
association, but only among the slum residents. However, perceiving people infected with COVID-19
as having a high death rate, perceived barriers such as serious side effects and long distances, and
depressive symptoms had negative associations with vaccine uptake among the slum community,
but not in the estate community. Addressing barriers to vaccination, strengthening and utilizing
the various cues to action, engagement of religious and cultural leaders, and continued community
education and sensitization tailored to the needs of each community are potentially vital strategies in
raising vaccination rates. Consideration of socioeconomic impact-alleviation strategies, especially
among the urban poor, would also be beneficial.
Description
Keywords
Slum-dwellers, Urban poor, COVID-19 vaccination, Uganda
Citation
Kawuki, J., Nambooze, J., Chan, P. S. F., Chen, S., Liang, X., Mo, P. K., & Wang, Z. (2023). Differential COVID-19 Vaccination Uptake and Associated Factors among the Slum and Estate Communities in Uganda: A Cross-Sectional Population-Based Survey. Vaccines, 11(2), 440.